Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

N-3 Fatty Acids for the Prevention of Atrial Fibrillation in Patients With Acute Heart Failure

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified June 2008 by Osaka General Medical Center.
Recruitment status was:  Not yet recruiting
Sponsor:
Information provided by:
Osaka General Medical Center
ClinicalTrials.gov Identifier:
NCT00692718
First received: May 29, 2008
Last updated: June 18, 2008
Last verified: June 2008
  Purpose
Our study is to investigate the effect of N-3 Fatty Acids for the prevention of atrial fibrillation in patients with acute heart failure or acute myocardial infarction

Condition Intervention Phase
Acute Heart Failure
Acute Myocardial Infarction
Drug: Epadel, Eicosapentaenoic acid
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Prevention
Official Title: N-3 Fatty Acids for the Prevention of Atrial Fibrillation in Patients With Acute Heart Failure

Resource links provided by NLM:


Further study details as provided by Osaka General Medical Center:

Primary Outcome Measures:
  • detection of atrial fibrillation on ECG monitoring [ Time Frame: anytime during hospitalization ] [ Designated as safety issue: No ]

Estimated Enrollment: 160
Study Start Date: July 2008
Estimated Primary Completion Date: June 2010 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: Epadel, Eicosapentaenoic acid
    Epadel 900mg, 2 times a day, during hospitalization
  Eligibility

Ages Eligible for Study:   20 Years and older   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • sinus rhythm patients with acute heart failure or acute myocardial infarction

Exclusion Criteria:

  • pregnancy,allergy to epadel
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

No Contacts or Locations Provided
  More Information

Responsible Party: Masaharu Masuda, Osaka Geneeal Medical Cener
ClinicalTrials.gov Identifier: NCT00692718     History of Changes
Other Study ID Numbers: OFAHeft 
Study First Received: May 29, 2008
Last Updated: June 18, 2008
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Heart Failure
Atrial Fibrillation
Infarction
Myocardial Infarction
Heart Diseases
Cardiovascular Diseases
Arrhythmias, Cardiac
Pathologic Processes
Ischemia
Necrosis
Myocardial Ischemia
Vascular Diseases
Eicosapentaenoic acid ethyl ester
Platelet Aggregation Inhibitors

ClinicalTrials.gov processed this record on December 09, 2016